{"nctId":"NCT02175212","briefTitle":"Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer","startDateStruct":{"date":"2005-11"},"conditions":["Prostate Adenocarcinoma"],"count":362,"armGroups":[{"label":"Long term androgen deprivation","type":"EXPERIMENTAL","interventionNames":["Drug: Long term androgen deprivation","Radiation: Long term androgen deprivation"]},{"label":"Short term androgen deprivation","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Short term androgen deprivation","Radiation: Short term androgen deprivation"]}],"interventions":[{"name":"Short term androgen deprivation","otherNames":["Neoadjuvant and concomitant"]},{"name":"Long term androgen deprivation","otherNames":["Neoadjuvant, concomitant and adjuvant"]},{"name":"Short term androgen deprivation","otherNames":[]},{"name":"Long term androgen deprivation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological proven adenocarcinoma of the prostate\n* Stage: cT1c-3b N0M0 according to American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM)\n* Prostatic Specific Antigen (PSA)\\<100 ng/ml\n* Intermediate (T1-T2 with Gleason Score \\[GS\\] 7 and/or PSA 10-20)\n* High risk (T3 and/or GS 8-10 and/or PSA \\> 20)\n* Karnofsky Index (KI) performance status â‰¥70%\n* Written informed consent\n\nExclusion Criteria:\n\n* T4 N1 M1,\n* Previous surgical treatment (prostatectomy or cryosurgery)\n* Neoadjuvant hormonal treatment \\> 3 months.\n* History of pelvic radiotherapy (RT)\n* Contraindications for radiotherapy\n* Concomitant use of chemotherapy\n* Serious psychiatric or medical condition\n* Current synchronic malignancies","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Biochemical Disease Free Survival: Estimated Percentage of Participants With Biochemical Disease-free Survival at 5 Years","description":"Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Metastasis Free Survival: Estimated Percentage of Participants With Metastasis-free Survival at 5 Years","description":"Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival: Estimated Percentage of Participants Alive at 5 Years","description":"Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Survival","description":"Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"173","spread":null}]}]}]},{"type":"SECONDARY","title":"Late Toxicity","description":"Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.\n\nScoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer-Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.\n\nCV events were defined according to the World Health Organization criteria","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":177},"commonTop":["Hot flashes","Rectal bleeding","Urinary toxicity","Asthenia"]}}}